gem-cesar trial: post-hoc analysis of sustained undetectable mrd in patients with high-risk smm
Published 1 year ago • 56 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
4:19
qip-ms in high-risk myeloma patients in the gem-cesar trial
-
3:53
comparison of mrd and conventional imwg response assessment in the gem-cesar trial
-
5:17
gmmg-concept: isa-krd in front-line treatment of high-risk myeloma
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
2:49
defining high-risk myeloma
-
2:07
defining high-risk myeloma: exciting updates and their implications
-
2:06
ims session highlights: high-risk myeloma
-
2:20
ultra high-risk myeloma
-
1:12
cytogenetic analysis from the perseus trial of dara-vrd in multiple myeloma
-
2:52
need for myeloma trials comparing new agents with auto-sct
-
2:08
gmmg-concept trial: isa-krd in high-risk newly diagnosed multiple myeloma
-
3:17
what new tests are on the horizon for myeloma monitoring?
-
6:05
updates in pv treatment: the efficacy of ropeginterferon alfa-2b
-
1:59
the role of upfront double auto-sct in high-risk myeloma
-
1:07
criteria used to define high-risk smm and how this is being improved
-
1:38
the genomic definition of high-risk myeloma
-
2:44
second interim analysis of the emn02 trial
-
4:30
next steps for myeloma research and treatment
-
3:28
molecular prognostication in smm